



LKT Laboratories, Inc.

XAV-939

Phone: 888-558-5227

651-644-8424

Fax: 888-558-7329

Email: getinfo@lctlabs.com

Web: lctlabs.com

Product Information

Product ID X0384

CAS No. 284028-89-3

Chemical Name 2-[4-(trifluoromethyl)phenyl]-7,8-dihydro-5H-thiino[4,3-d]pyrimidin-4-ol

Synonym


Formula $C_{14}H_{11}F_3N_2OS$

Formula Wt. 312.31

Melting Point

Purity $\geq 95\%$

Solubility DMSO (25mg/ml)



Pricing and Availability

Bulk quantities available upon request

Product ID	Size	List Price
X0384	5 mg	\$52.00
X0384	25 mg	\$213.00

Store Temp -20°C

Ship Temp Ambient

Description XAV-939 inhibits tankyrases and wnt pathway signaling. XAV exhibits anti-fibrotic activity and shows potential anticancer chemotherapeutic benefit when co-administered with other compounds. XAV-939 decreases nuclear accumulation of β -catenin and decreases c-myc levels, decreasing bleomycin-induced dermal thickening. In both in vitro and in vivo models of cancer, this compound reverses resistance to PI3K and Akt inhibitors.

References Bilir B, Kucuk O, Moreno CS. Wnt signaling blockage inhibits cell proliferation and migration, and induces apoptosis in triple-negative breast cancer cells. *J Transl Med.* 2013 Nov 4;11(1):280. [Epub ahead of print]. PMID: 24188694

Distler A, Deloch L, Huang J, et al. Inactivation of tankyrases reduces experimental fibrosis by inhibiting canonical Wnt signalling. *Ann Rheum Dis.* 2013 Sep 1;72(9):1575-80. PMID: 23148305.

Tenbaum SP, Ordóñez-Morán P, Puig I, et al. β -catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer. *Nat Med.* 2012 Jun;18(6):892-901. PMID: 22610277.

Caution: This product is intended for laboratory and research use only. It is not for human or drug use.